<3930> Hatena 767 -2

After the rise, there is a stalemate. After the trading on the 31st, it was announced that Mackerel was adopted in the integrated monitoring service "MoniPro M" offered by SCSK from July 31, 24, which started to rise but was pushed down by the market. Mackerel is a SaaS server monitoring service that can be used in various environments such as on-premises and multi-cloud, and in cooperation with SCSK, it will support the monitoring of cloud/hybrid environments for MoniPro users.

＜4564＞ OTS 60 +12

Marked increase, reaching a new high for the year. On July 30th, the publication of the results paper for the S-588410 Phase III clinical trial targeting esophageal cancer patients was announced, and the company continues to be well received. The paper summarizes the results of the Phase III clinical trial targeting esophageal cancer patients for the S-588410 cancer-specific peptide vaccine licensed out to Shionogi & Co., Ltd., and is published in the journal Esophagus. The patent acquisition of a breast cancer treatment drug which includes a PHB2-derived peptide inhibiting the BIG3-PHB2 interaction is also being considered as a material.

＜6537＞ WASH House 473 -100

The stock price has hit the limit down for two consecutive days, which was triggered by the limit down delivery on July 31. Although there is no significant negative news, it seems that the current downturn is due to the overall bearish market and a correction after a rapid rise following the announcement of the expansion of container-type self-laundry stores as a new business.

＜4015＞ PayCLOUD 611 +44

A significant rebound. After the closing of trading on the 31st, the company announced the introduction of a shareholder benefit system and was well received. Shareholders who hold 300 shares (3 units) or more recorded in or recorded on the shareholder register as of the end of August every year (regardless of the holding period) will be presented with a digital gift of 5,000 yen for less than 500 shares and a digital gift of 10,000 yen uniformly for 500 or more shares. You can choose one of the digital gifts issued by companies that introduce the electronic money "original Pay" service provided by a group company Value Design.

＜3542＞ VEGA 741 +93

At one point, the stock price hit the limit up. After the trading session on July 31, the first quarter results for the fiscal year 2025 were announced and well-received. The operating profit was 0.202 billion yen (compared to an operating loss of 0.034 billion yen in the same period last year), ordinary profit was 0.203 billion yen (compared to an ordinary loss of 0.029 billion yen in the same period last year), and net profit for the quarter was 0.13 billion yen (compared to a net loss of 0.019 billion yen in the same period last year). These results were achieved by continuing efforts to improve profits, focusing on optimizing marketing costs, reducing personnel and fixed costs.

＜4592＞ Sun Bio 1110 -6

The stock price is in a stalemate. After the trading session on July 31st, they announced that they have obtained conditional and time-limited manufacturing and sales approval for "Acugo Intracerebral Transplantation for the Brain" (generic name: Bandefitemu cell), a drug for improving chronic motor paralysis caused by traumatic brain injury. Acugo is expected to promote nerve cell proliferation and differentiation by promoting the regenerative ability of damaged nerve cells through the transplantation of multiple proteins into damaged brain tissue. In addition, protective effects on nerve cells, promotion of angiogenesis, and immunomodulatory effects have been reported based on the results of basic experiments.